Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H1 2018
Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H1 2018
SUMMARY
Catenin Beta 1 (Beta Catenin or CTNNB1) - Catenin beta-1 or ?-catenin is a protein that is encoded by the CTNNB1 gene. In the presence of Wnt ligand, CTNNB1 acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. It is involved in the regulation of cell adhesion, CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. It also acts as a negative regulator of centrosome cohesion. It blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2.
Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 13 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical, Discovery and Unknown stages are 2, 4, 3 and 1 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology, Genetic Disorders and Non Malignant Disorders which include indications Colorectal Cancer, Familial Adenomatous Polyposis, Hemangiomas, Hepatic (Liver) Tumor, Melanoma, Ovarian Cancer, Pancreatic Cancer, Scar and Solid Tumor.
The latest report Catenin Beta 1 - Pipeline Review, H1 2018, outlays comprehensive information on the Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Catenin Beta 1 (Beta Catenin or CTNNB1) - Catenin beta-1 or ?-catenin is a protein that is encoded by the CTNNB1 gene. In the presence of Wnt ligand, CTNNB1 acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. It is involved in the regulation of cell adhesion, CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. It also acts as a negative regulator of centrosome cohesion. It blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2.
Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 13 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical, Discovery and Unknown stages are 2, 4, 3 and 1 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology, Genetic Disorders and Non Malignant Disorders which include indications Colorectal Cancer, Familial Adenomatous Polyposis, Hemangiomas, Hepatic (Liver) Tumor, Melanoma, Ovarian Cancer, Pancreatic Cancer, Scar and Solid Tumor.
The latest report Catenin Beta 1 - Pipeline Review, H1 2018, outlays comprehensive information on the Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Catenin Beta 1 (Beta Catenin or CTNNB1)
- The report reviews Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Catenin Beta 1 (Beta Catenin or CTNNB1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Catenin Beta 1 (Beta Catenin or CTNNB1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Catenin Beta 1 (Beta Catenin or CTNNB1) - Overview
Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Catenin Beta 1 (Beta Catenin or CTNNB1) - Companies Involved in Therapeutics Development
Boston Biomedical Inc
Marina Biotech Inc
Propanc Biopharma Inc
Warp Drive Bio Inc
Catenin Beta 1 (Beta Catenin or CTNNB1) - Drug Profiles
BBI-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
exisulind - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nefopam hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotides for Hepatoblastoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRP - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit Beta Catenin for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VTX-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WX-024 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Catenin Beta 1 (Beta Catenin or CTNNB1) - Dormant Products
Catenin Beta 1 (Beta Catenin or CTNNB1) - Product Development Milestones
Featured News & Press Releases
Mar 14, 2018: Propanc Biopharma Completes Successful Reproduction Run for PRP
Feb 20, 2018: Propanc Biopharma Receives Allowance of Key Patent Application in the EU
Dec 28, 2017: Propanc Biopharma to Present at the 10th Annual Biotech Showcase 2018
Nov 27, 2017: Propanc Biopharma to Present at the 10th Annual LD Micro Main Event
Oct 19, 2017: Propanc Biopharma Publishes Key Scientific Data in Peer Reviewed Journal
Sep 27, 2017: Propanc Biopharma Highlights Therapeutic Potential of PRP
Aug 30, 2017: Propanc Biopharma Provides Shareholder Update for PRP on Current and Future Activities Leading to Commencement of First-In-Human Studies
Aug 02, 2017: Propanc Biopharma Confirms No Treatment Related Findings for PRP in 28-Day Repeat-Dose Toxicity Study
Jul 27, 2017: Propanc Biopharma Provides Shareholder Update on R&D Activities for PRP
Jul 20, 2017: Propanc Biopharma Receives Acceptance of Key Patent Application for Cancer Treatment in China
Jun 27, 2017: ScarX Achieves Full Enrollment in Human Scar Reduction Trial Safety and Efficacy Results Targeted for Late 2017
Jun 26, 2017: Propanc Biopharma Receives Orphan Drug Designation from FDA for Treatment of Pancreatic Cancer
Jun 09, 2017: Propanc Biopharma Makes Significant Progress with PCT Patent Application
May 19, 2017: Propanc Biopharma Highlights PRP's Potential to Reprogram Cancer Stem Cells
May 16, 2017: Propanc Biopharma Awaits FDA Response to Orphan Drug Designation Request for Treatment of Pancreatic Cancer, as PRP Progresses to First-In-Human Studies
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Catenin Beta 1 (Beta Catenin or CTNNB1) - Overview
Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Catenin Beta 1 (Beta Catenin or CTNNB1) - Companies Involved in Therapeutics Development
Boston Biomedical Inc
Marina Biotech Inc
Propanc Biopharma Inc
Warp Drive Bio Inc
Catenin Beta 1 (Beta Catenin or CTNNB1) - Drug Profiles
BBI-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
exisulind - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nefopam hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotides for Hepatoblastoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRP - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit Beta Catenin for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VTX-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WX-024 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Catenin Beta 1 (Beta Catenin or CTNNB1) - Dormant Products
Catenin Beta 1 (Beta Catenin or CTNNB1) - Product Development Milestones
Featured News & Press Releases
Mar 14, 2018: Propanc Biopharma Completes Successful Reproduction Run for PRP
Feb 20, 2018: Propanc Biopharma Receives Allowance of Key Patent Application in the EU
Dec 28, 2017: Propanc Biopharma to Present at the 10th Annual Biotech Showcase 2018
Nov 27, 2017: Propanc Biopharma to Present at the 10th Annual LD Micro Main Event
Oct 19, 2017: Propanc Biopharma Publishes Key Scientific Data in Peer Reviewed Journal
Sep 27, 2017: Propanc Biopharma Highlights Therapeutic Potential of PRP
Aug 30, 2017: Propanc Biopharma Provides Shareholder Update for PRP on Current and Future Activities Leading to Commencement of First-In-Human Studies
Aug 02, 2017: Propanc Biopharma Confirms No Treatment Related Findings for PRP in 28-Day Repeat-Dose Toxicity Study
Jul 27, 2017: Propanc Biopharma Provides Shareholder Update on R&D Activities for PRP
Jul 20, 2017: Propanc Biopharma Receives Acceptance of Key Patent Application for Cancer Treatment in China
Jun 27, 2017: ScarX Achieves Full Enrollment in Human Scar Reduction Trial Safety and Efficacy Results Targeted for Late 2017
Jun 26, 2017: Propanc Biopharma Receives Orphan Drug Designation from FDA for Treatment of Pancreatic Cancer
Jun 09, 2017: Propanc Biopharma Makes Significant Progress with PCT Patent Application
May 19, 2017: Propanc Biopharma Highlights PRP's Potential to Reprogram Cancer Stem Cells
May 16, 2017: Propanc Biopharma Awaits FDA Response to Orphan Drug Designation Request for Treatment of Pancreatic Cancer, as PRP Progresses to First-In-Human Studies
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Boston Biomedical Inc, H1 2018
Pipeline by Marina Biotech Inc, H1 2018
Pipeline by Propanc Biopharma Inc, H1 2018
Pipeline by Warp Drive Bio Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Boston Biomedical Inc, H1 2018
Pipeline by Marina Biotech Inc, H1 2018
Pipeline by Propanc Biopharma Inc, H1 2018
Pipeline by Warp Drive Bio Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Boston Biomedical Inc
Marina Biotech Inc
Propanc Biopharma Inc
Warp Drive Bio Inc
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Boston Biomedical Inc
Marina Biotech Inc
Propanc Biopharma Inc
Warp Drive Bio Inc
